PDF(Pubmed)
Abstract：
UNASSIGNED: Despite many attempts to treat leishmaniasis, new approaches are necessary to reduce the burden of disease. Perovskia abrotanoides (Brazambel) has shown significant effects against Leishmania parasites in some studies. This study aimed to investigate the effects of P. abrotanoides extract topical formulation on cutaneous leishmaniasis.
UNASSIGNED: In this randomized controlled clinical trial, patients with cutaneous leishmaniasis were assigned to experimental (n = 18) and control (n = 18) groups. Both groups received intralesional meglumine antimoniate (Glucantime®). The experimental group also received 5% Brazambel extract ointment once a day. The interventions continued until the complete healing of the lesions (reepithelialization) for a maximum of 8 weeks. The clinical response, defined as complete response (reepithelialization >75%), partial response (reepithelialization 50%-75%), or treatment failure (reepithelialization <50%), was compared between the groups.
UNASSIGNED: The percentage of reepithelialization in the experimental group (4th week: 64.44 ± 25.13; 8th week: 83.85 ± 11.54) was higher than the control group (4th week: 53.97 ± 25.88; 8th week: 76.27 ± 21.67); however, the differences were not statistically significant (P = 0.252 and 0.494, respectively). Moreover, there was no significant difference between the experimental and control groups regarding the rate of complete healing (88.9% vs. 72.2%, respectively).
UNASSIGNED: The use of P. abrotanoides extract 5% topical formulation does not affect the healing of cutaneous leishmaniasis.
UNASSIGNED: In this randomized controlled clinical trial, patients with cutaneous leishmaniasis were assigned to experimental (n = 18) and control (n = 18) groups. Both groups received intralesional meglumine antimoniate (Glucantime®). The experimental group also received 5% Brazambel extract ointment once a day. The interventions continued until the complete healing of the lesions (reepithelialization) for a maximum of 8 weeks. The clinical response, defined as complete response (reepithelialization >75%), partial response (reepithelialization 50%-75%), or treatment failure (reepithelialization <50%), was compared between the groups.
UNASSIGNED: The percentage of reepithelialization in the experimental group (4th week: 64.44 ± 25.13; 8th week: 83.85 ± 11.54) was higher than the control group (4th week: 53.97 ± 25.88; 8th week: 76.27 ± 21.67); however, the differences were not statistically significant (P = 0.252 and 0.494, respectively). Moreover, there was no significant difference between the experimental and control groups regarding the rate of complete healing (88.9% vs. 72.2%, respectively).
UNASSIGNED: The use of P. abrotanoides extract 5% topical formulation does not affect the healing of cutaneous leishmaniasis.
摘要：
■尽管许多尝试治疗利什曼病，有必要采取新的方法来减轻疾病负担。在一些研究中，Perovskiaabrotanoides（Brazambel）对利什曼原虫寄生虫具有显着的作用。本研究旨在研究巴豆提取物外用制剂对皮肤利什曼病的影响。
■在这项随机对照临床试验中，皮肤利什曼病患者被分为实验组(n=18)和对照组(n=18).两组均接受病灶内的锑酸葡甲胺(Glucantime®)。实验组还每天一次接受5%Brazambel提取物软膏。干预持续至病变完全愈合(再上皮化)最长8周。临床反应，定义为完全反应(上皮再生>75%)，部分反应（上皮再生50%-75%），或治疗失败（上皮再生<50％），进行组间比较。
■实验组（第4周：64.44±25.13；第8周：83.85±11.54）的再上皮形成百分比高于对照组（第4周：53.97±25.88；第8周：76.27±21.67）；但是，差异无统计学意义(分别为P=0.252和0.494).此外，在完全愈合率方面，实验组和对照组之间没有显着差异（88.9％vs.72.2%,分别)。
■使用巴豆提取物5%局部制剂不影响皮肤利什曼病的愈合。
■在这项随机对照临床试验中，皮肤利什曼病患者被分为实验组(n=18)和对照组(n=18).两组均接受病灶内的锑酸葡甲胺(Glucantime®)。实验组还每天一次接受5%Brazambel提取物软膏。干预持续至病变完全愈合(再上皮化)最长8周。临床反应，定义为完全反应(上皮再生>75%)，部分反应（上皮再生50%-75%），或治疗失败（上皮再生<50％），进行组间比较。
■实验组（第4周：64.44±25.13；第8周：83.85±11.54）的再上皮形成百分比高于对照组（第4周：53.97±25.88；第8周：76.27±21.67）；但是，差异无统计学意义(分别为P=0.252和0.494).此外，在完全愈合率方面，实验组和对照组之间没有显着差异（88.9％vs.72.2%,分别)。
■使用巴豆提取物5%局部制剂不影响皮肤利什曼病的愈合。
